Evidence map›Paper›PMID 25893172›Full record

ArticlePhotoacoustics2015

Melanin nanoparticles as a novel contrast agent for optoacoustic tomography.

Anton Liopo, Richard Su, Alexander A Oraevsky

Abstract read
In one paragraph

Article in Photoacoustics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Melanin-Like Nanomedicine in Photothermal Therapy Applications.International journal of molecular sciences · 2021
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anton LiopoTomoWave Laboratories, Houston Texas 77081, United States.
Richard SuTomoWave Laboratories, Houston Texas 77081, United States.
Alexander A OraevskyTomoWave Laboratories, Houston Texas 77081, United States.

Funding

Optoacoustic imaging enhanced by gold nanorodsR44CA110137 · NCI · TOMOWAVE LABORATORIES, INC. · PI ORAEVSKY, ALEXANDER A · 2005 to 2009
$3.1M
Optoacoustic system for monitoring biodistribution of nanoparticles in vivo.R43ES021629 · NIEHS · TOMOWAVE LABORATORIES, INC. · PI ORAEVSKY, ALEXANDER A · 2011 to 2011
$115k
NCI NIH HHS R44 CA110137NIEHS NIH HHS R43 ES021629
6 · The paper itself

Abstract

We describe the synthesis and characterization of melanin-like nanoparticles (MNP) as novel contrast agents for optoacoustic tomography. Good dispersion stability of high concentration MNPs in different biological media was achieved with thiol-terminated methoxy-poly(ethylene glycol), which can be used for further functional conjugation. MNP-PEG were found biocompatible with human MCF-7 and 3T3 cells. Cell toxicity of MNPs was found lower than that of gold nanorods for concentrations that provide equal optical absorbance. Optoacoustic tomography images were obtained with Laser Optoacoustic Imaging System (LOIS-3D) from tubes filled with contrast agents and live mice. Imaging of tubes permitted verification of the system resolution <300 μm and sensitivity Δμa=0.03/cm under safe laser fluence of 20 mJ/cm(2). Water suspensions of MNP demonstrated optoacoustic efficiency that is about equal to that of gold nanorods under conditions of equal optical absorption. We conclude that MNPs have the potential for biomedical imaging applications as optoacoustic contrast agents.

Indexed as

gold nanorod nanoparticlesimage contrastmelanin nanoparticlesOptoacousticphotoacoustic

Identifiers

PMID25893172
PMCPMC4398798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.